(Reuters) Israel's IceCure Medical said on Sunday it received U.S. FDA approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys. IceCure uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery.
2019-12-24 00:00:00Full ArticleBACK Visit the Daily Alert Archive